Interactions between mu and kappa opioid agonists in the rat drug discrimination procedure

Psychopharmacology

Volumn 102, Issue 4, 1990, Pages 465-473

  Negus, S Stevens ^a   Picker, Mitchell J ^a   Dykstra, Linda A ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Bremazocine; Buprenorphine; Drug discrimination; Fentanyl; Morphine; Opioid interactions; Tifluadom; U50,488

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; BREMAZOCINE; BUPRENORPHINE; FENTANYL; KAPPA OPIATE RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; TIFLUADOM;

ANIMAL EXPERIMENT; ARTICLE; DRUG DISCRIMINATION; DRUG INTERACTION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; ANIMAL; BENZODIAZEPINES; BENZOMORPHANS; BUPRENORPHINE; DISCRIMINATION (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FENTANYL; MALE; MORPHINE; PENTOBARBITAL; PYRROLIDINES; RATS; RECEPTORS, OPIOID; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0025175254     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/BF02247126     Document Type: Article

References (56)

1. Classification of drugs according to their discriminable effects in rats
2. Antinociceptive actions of morphine and buprenorphine given intrathecally in the conscious rat
3. Heterogeneity and properties of opiate receptors
4. Agonist and antagonist effects of prototype opiate drugs in rats discriminating fentanyl from saline: characteristics of partial generalization
5. Effects of tifluadom on food consumption compared with chlordiazepoxide and kappa agonists in the rat
6. Bremazocine is an agonist at k-opioid receptors and an antagonist at μ-opioid receptors in guinea-pig myenteric plexus
7. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent
8. Studies in vivo with ICI174,864 and [D-Pen2, D-Pen5] enkephalin
9. Distinct subtypes of the opioid receptor with allosteric interactions in brain membranes
10. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats
11. Differential cross-tolerance to opioid agonists in morphine-tolerant squirrel monkeys responding under a schedule of food presentation
12. Buprenorphine: demonstration of physical dependence liability
13. Effects of buprenorphine on shock titration in squirrel monkeys
14. Antagonism of the analgesic effects of mu and kappa opioid agonists in the squirrel monkey
15. Discriminative stimulus effects of reversible and irreversible opiate agonists: morphine, oxymorphazone and buprenorphine
16. Perceptual masking of drug stimuli
17. Evidence for perceptual masking of the discriminative morphine stimulus
18. Tifluadom's effects under electric shock titration and tail-immersion procedures in squirrel monkeys
19. Profile of activity of k receptor agonists in the rabbit vas deferens
20. Differential sensitivity of models of antinociception in the rat, mouse and guinea-pig to mu- and kappa-opioid receptor agonists
21. Evidence for κ, μ and δ opioid binding site interactions in vivo
22. Discriminative stimulus properties of opioids that interact with mu, kappa and PCP/Sigma receptors
23. Identification of distinct binding site subunits of mu and delta opioid receptors
24. K-opiates and urination: pharmacological evidence for an endogenous role of the K-opiate receptor in fluid and electrolyte balance
25. The role of opioid receptor sub-types in tifluadom-induced feeding
26. Novel peptidic mu opioid antagonists: pharmacologic characterization in vitro and in vivo
27. A kappa opioid effect: increased urination in the rat
28. Further study of kappa opioids on increased urination
29. K-opioid diuretic effects of tifluadom, a benzodiazepine opioid agonist
30. Behavioral effects of agonist and antagonist actions at kappa opioid receptors
31. Buprenorphine has potent kappa opioid receptor antagonist activity
32. Endogenous opioid peptides: multiple agonists and receptors
33. The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties
34. Anatomy of CNS opioid receptors
35. The effects of morphine- and nalorphine-like drugs in the non-dependent and morphine-dependent chronic spinal dog
36. Motivational properties of kappa- and mu- opioid receptor agonists studied with place and taste preference conditioning procedures
37. Kappa antagonist properties of buprenorphine in the shock titration procedure
38. Kappa antagonist properties of buprenorphine in non-tolerant and morphine-tolerant rats
39. Effects of nimodipine on the discriminative stimulus properties of d-amphetamine in rats
40. Similarities and differences between behavioral control by drug-produced stimuli and by sensory stimuli
41. Bremazocine induces antinociception, but prevents opioid-induced constipation and catatonia in rats and precipitates withdrawal in morphine-dependent rats
42. Discriminative stimulus properties of U50,488 and morphine: effects of training dose on stimulus substitution patterns produced by mu and kappa opioid agonists
43. Effect of k-opioid receptor agonists on morphine analgesia in morphine-naive and morphine-tolerant rats
44. Buprenorphine is an antagonist at the kappa opioid receptor
45. Bremazocine: a potent, long-acting opiate kappa agonist
46. Allosteric coupling between morphine and enkephalin receptors in vitro
47. Chronic administration of morphine and naltrexone up-regulate mu-opioid binding sites labeled by [3H]D-Ala2,MePhe4,Gly-ol5]enkephalin: further evidence for two mu-opioid binding sites
48. Morphine-like discriminative stimulus effects of buprenorphine and demethoxybuprenorphine in rats: quantitative antagonism by naloxone
49. Mu antagonist properties of kappa agonists in a model of urinary bladder motility in vivo
50. Selective protection of stereospecific enkephalin and opiate binding against inactivation by N-ethylmaleimide: evidence for two classes of opiate receptors
51. Norbinaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor-binding assays
52. K-opiate-induced diuresis and changes in blood pressure: demonstration of receptor stereoselectivity using (+)- and (−)-tifluadom
53. U50,488: a selective and structurally novel non-mu (kappa) opioid agonist
54. Multiple opiate receptors: differential binding of mu, kappa and delta agonists
55. Multiple opiate receptor affinities of kappa and agonist/antagonist analgesics: in vivo assessment